Screener
Castle Biosciences CSTL EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
FAQ
- What is Castle Biosciences's EPS (diluted)?
- Castle Biosciences (CSTL) reported EPS (diluted) of -$0.49 in Q1 2026.
- How has Castle Biosciences's EPS (diluted) changed year-over-year?
- Castle Biosciences's EPS (diluted) increased by 45.6% year-over-year, from -$0.90 to -$0.49.
- What is the long-term trend for Castle Biosciences's EPS (diluted)?
- Over 4 years (2021 to 2025), Castle Biosciences's EPS (diluted) has grown at a -9.3% compound annual growth rate (CAGR), from -$1.24 to -$0.84.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Castle Biosciences's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude